- Home
- FIS vs ASND Comparison
FIS vs ASND Comparison
Compare FIS & ASND Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | FIS | ASND |
|---|---|---|
| Founded | 1968 | 2006 |
| Country | United States | Denmark |
| Employees | N/A | N/A |
| Industry | Business Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 20.7B | 17.7B |
| IPO Year | 2001 | 2014 |
Fundamental Metrics
Financial Performance| Metric | FIS | ASND |
|---|---|---|
| Price | $34.98 | $237.57 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 14 | 16 |
| Target Price | $72.23 | ★ $281.50 |
| AVG Volume (30 Days) | ★ 4.8M | 643.5K |
| Earning Date | 05-08-2026 | 05-12-2026 |
| Dividend Yield | ★ 3.81% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 5.03 | N/A |
| Revenue | ★ $10,677,000,000.00 | N/A |
| Revenue This Year | $30.41 | $96.35 |
| Revenue Next Year | $4.76 | $44.91 |
| P/E Ratio | $7.00 | ★ N/A |
| Revenue Growth | ★ 5.43 | N/A |
| 52 Week Low | $35.19 | $186.05 |
| 52 Week High | $69.14 | $282.15 |
Technical Indicators
Market Signals| Indicator | FIS | ASND |
|---|---|---|
| Relative Strength Index (RSI) | 30.80 | 37.73 |
| Support Level | N/A | $235.71 |
| Resistance Level | $43.83 | $249.89 |
| Average True Range (ATR) | 1.19 | 9.21 |
| MACD | -0.40 | -3.20 |
| Stochastic Oscillator | 6.48 | 19.83 |
Price Performance
Historical ComparisonAbout FIS Fidelity National Information Services Inc.
Fidelity National Information Services provides core processing and ancillary services to banks, but its business has expanded over time. By acquiring SunGard in 2015, the company now provides record-keeping and other services to investment firms. In a recent deal with Global Payments, FIS sold off its remaining interest in Worldpay and acquired Global Payment's issuer processing business.
About ASND Ascendis Pharma A/S
Ascendis Pharma AS is a biopharmaceutical company that applies its TransCon technology platform to make a meaningful difference for patients. The firm's product pipeline includes Endocrinology and Oncology, which includes TransCon PTH, TransCon CNP, and others. It operates in the United States, Europe, and the rest of the world and derives the majority of its revenue from the United States.